SB202190

SB202190 is a highly selective, potent, and cell-permeable small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK), specifically targeting the p38α (MAPK14, SAPK2A) and p38β (MAPK11, SAPK2B) isoforms with low nanomolar inhibitory concentrations. SB202190 binds within the ATP pocket of the active kinase, competitively inhibiting kinase activity[4][5][8]. It is extensively used in research to dissect p38-mediated signal transduction pathways, including investigations into stress response, autophagy, cell cycle, apoptosis, lysosomal biogenesis, and cancer biology[1][3][6][9]. SB202190 has also been shown to inhibit UVB-induced COX-2 expression and modulate nuclear localization of transcription factors, such as FoxO3A, and to impact tumor proliferation and autophagic flux in cell and animal models[1][3][10]. Structurally, it belongs to the pyridinyl imidazole class of kinase inhibitors.

Other names

FHPI4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-phenol